IDELALISIB
idelalisib 150 mg tablet, 60
IDELALISIB (11162L)
11162L
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Initial treatment
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $5,119.79 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Zydelig | |||||